What is Bioxytran Inc's earnings per share (EPS)?

Bioxytran Inc (BIXT) reported diluted earnings per share of $-0.02 for fiscal year 2024. This represents a 33.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bioxytran Inc Financials

BIXT

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Bioxytran Inc (BIXT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Bioxytran Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.02x

For every $1 of reported earnings, Bioxytran Inc generates $0.02 in operating cash flow (-$56K OCF vs -$2.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-26.4x

Bioxytran Inc earns $-26.4 in operating income for every $1 of interest expense (-$2.2M vs $84K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$2.4M

YoY+47.1%

Bioxytran Inc reported -$2.4M in net income in fiscal year 2024. This represents an increase of 47.1% from the prior year.

EPS (Diluted)

$-0.02

YoY+33.3%

Bioxytran Inc earned $-0.02 per diluted share (EPS) in fiscal year 2024. This represents an increase of 33.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$5K

YoY-80.2%

5Y CAGR-50.3%

10Y CAGR-1.8%

Bioxytran Inc held $5K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

88M

YoY-39.1%

5Y CAGR+0.4%

Bioxytran Inc had 88M shares outstanding in fiscal year 2024. This represents a decrease of 39.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$112K

YoY-90.2%

Bioxytran Inc invested $112K in research and development in fiscal year 2024. This represents a decrease of 90.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BIXT Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$112K-90.2%	$1.1M-10.1%	$1.3M-36.5%	$2.0M+269.8%	$545K	N/A
SG&A Expenses	$1.2M-16.8%	$1.4M+68.1%	$835K-48.2%	$1.6M+238.6%	$476K-6.1%	$507K
Operating Income	-$2.2M+41.5%	-$3.8M-56.0%	-$2.4M+42.2%	-$4.2M-232.2%	-$1.3M+22.2%	-$1.6M
Interest Expense	$84K-56.4%	$193K	N/A	$2.0M+99.1%	$1.0M+2325.1%	$42K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.4M+47.1%	-$4.5M-80.8%	-$2.5M+38.7%	-$4.0M-58.6%	-$2.5M-36.8%	-$1.9M
EPS (Diluted)	$-0.02+33.3%	$-0.03-50.0%	$-0.02	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$103K-70.7%	$350K	N/A	$51K	N/A	$27K	N/A
SG&A Expenses	$159K+59.9%	$100K-33.1%	$149K	N/A	$158K-64.7%	$448K+39.5%	$321K	N/A
Operating Income	-$496K-121.4%	-$224K+56.5%	-$515K	N/A	-$346K+43.2%	-$609K+21.8%	-$779K	N/A
Interest Expense	$37K+21.3%	$30K-3.4%	$31K	N/A	$18K-9.6%	$20K-25.2%	$26K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$283K-897.8%	$35K+102.6%	-$1.4M	N/A	-$392K+40.7%	-$662K-18.0%	-$561K	N/A
EPS (Diluted)	$0.00	$0.00+100.0%	$-0.02	N/A	$0.00	$0.00	$0.00	N/A

BIXT Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$139K-0.5%	$139K-62.4%	$371K+211.0%	$119K-63.5%	$326K+48.6%	$220K
Current Assets	$5K-80.2%	$26K-91.2%	$295K+308.2%	$72K-77.1%	$316K+44.1%	$220K
Cash & Equivalents	$5K-80.2%	$26K-91.2%	$295K+308.2%	$72K+73.6%	$42K-75.4%	$170K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$50K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.9M-40.5%	$3.2M-11.6%	$3.7M+11.9%	$3.3M+44.5%	$2.3M+122.6%	$1.0M
Current Liabilities	$1.9M-40.5%	$3.2M-11.6%	$3.7M+11.9%	$3.3M+44.5%	$2.3M+122.6%	$1.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.8M+42.3%	-$3.1M+5.8%	-$3.3M-4.4%	-$3.2M-62.7%	-$1.9M-142.9%	-$799K
Retained Earnings	-$18.9M-20.5%	-$15.7M-39.8%	-$11.2M-28.3%	-$8.8M-85.4%	-$4.7M-110.7%	-$2.2M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$156K+6.0%	$148K+8.4%	$136K-1.9%	$139K-12.8%	$159K+23.7%	$129K+2.4%	$126K-9.9%	$139K
Current Assets	$14K+361.2%	$3K-27.7%	$4K-15.6%	$5K-85.1%	$35K+156.4%	$14K+34.9%	$10K-61.6%	$26K
Cash & Equivalents	$14K+361.2%	$3K-27.7%	$4K-15.6%	$5K-85.1%	$35K+156.4%	$14K+34.9%	$10K-61.6%	$26K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.1M+10.0%	$2.8M-2.2%	$2.8M+47.3%	$1.9M+55.2%	$1.2M+1.2%	$1.2M+10.1%	$1.1M-65.6%	$3.2M
Current Liabilities	$3.1M+10.0%	$2.8M-2.2%	$2.8M+47.3%	$1.9M+55.2%	$1.2M+1.2%	$1.2M+10.1%	$1.1M-65.6%	$3.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.9M-10.2%	-$2.6M+2.7%	-$2.7M-51.1%	-$1.8M-65.2%	-$1.1M+1.4%	-$1.1M-11.1%	-$990K+68.1%	-$3.1M
Retained Earnings	-$20.5M-1.4%	-$20.2M+0.2%	-$20.3M-7.2%	-$18.9M-3.4%	-$18.3M-7.9%	-$17.0M-4.1%	-$16.3M-3.8%	-$15.7M

BIXT Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$56K+92.8%	-$775K+57.0%	-$1.8M-6.3%	-$1.7M-54.5%	-$1.1M-155.0%	-$431K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$28K+36.4%	-$44K-37.4%	-$32K+12.7%	-$37K-269.3%	-$10K	N/A
Financing Cash Flow	$63K-88.6%	$550K-73.3%	$2.1M+16.7%	$1.8M+79.9%	$981K+73.9%	$564K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$41K+48.6%	-$81K+51.8%	-$167K-184.7%	$198K+368.7%	-$74K-4.7%	-$70K+35.9%	-$110K-18.3%	-$93K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$2K+89.0%	-$15K-100980.0%	-$15+99.9%	-$12K-11.6%	-$11K-1661.5%	$693+111.6%	-$6K+8.6%	-$7K
Financing Cash Flow	$55K-42.4%	$95K-43.2%	$167K+177.4%	-$215K-303.8%	$106K+44.4%	$73K-26.6%	$100K+121.1%	$45K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BIXT Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-1706.4%+1502.4pp	-3208.8%-2542.1pp	-666.7%+2713.1pp	-3379.8%-2600.8pp	-779.0%+67.2pp	-846.2%
Current Ratio	0.000.0	0.01-0.1	0.08+0.1	0.02-0.1	0.14-0.1	0.22
Debt-to-Equity	-1.08-0.0	-1.04+0.1	-1.11-0.1	-1.04+0.1	-1.17+0.1	-1.27
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-180.9%-204.9pp	24.0%+1019.0pp	-994.9%	N/A	-246.8%+267.9pp	-514.7%-68.2pp	-446.5%	N/A
Current Ratio	0.000.0	0.000.0	0.000.0	0.00-0.0	0.03+0.0	0.010.0	0.010.0	0.01
Debt-to-Equity	-1.050.0	-1.060.0	-1.05+0.0	-1.08+0.1	-1.15-0.0	-1.120.0	-1.13-0.1	-1.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Inhibitor Therap INTI

$15.5M

Glow Lifetech GLWLF

$7.4M

Biophytis Sa BPTSY

$4.6M

Betterlife Pharma Inc BETRF

$7.1M

Pharmala Biotech MDXXF

$8.1M

Frequently Asked Questions

Is Bioxytran Inc profitable?

No, Bioxytran Inc (BIXT) reported a net income of -$2.4M in fiscal year 2024.

What is Bioxytran Inc's operating cash flow?

Bioxytran Inc (BIXT) generated -$56K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Bioxytran Inc's total assets?

Bioxytran Inc (BIXT) had $139K in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Bioxytran Inc spend on research and development?

Bioxytran Inc (BIXT) invested $112K in research and development during fiscal year 2024.

How many shares does Bioxytran Inc have outstanding?

Bioxytran Inc (BIXT) had 88M shares outstanding as of fiscal year 2024.

What is Bioxytran Inc's current ratio?

Bioxytran Inc (BIXT) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Bioxytran Inc's debt-to-equity ratio?

Bioxytran Inc (BIXT) had a debt-to-equity ratio of -1.08 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bioxytran Inc's return on assets (ROA)?

Bioxytran Inc (BIXT) had a return on assets of -1706.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Bioxytran Inc's cash runway?

Based on fiscal year 2024 data, Bioxytran Inc (BIXT) had $5K in cash against an annual operating cash burn of $56K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Bioxytran Inc's debt-to-equity ratio negative or unusual?

Bioxytran Inc (BIXT) has negative shareholder equity of -$1.8M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Bioxytran Inc's Piotroski F-Score?

Bioxytran Inc (BIXT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bioxytran Inc's earnings high quality?

Bioxytran Inc (BIXT) has an earnings quality ratio of 0.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bioxytran Inc cover its interest payments?

Bioxytran Inc (BIXT) has an interest coverage ratio of -26.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.